mRNA Therapeutics Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 39.1 billion
Estimated Base Value
2035 Forecast
US$ 259.4 billion
Projected Market Value
CAGR 2026–2035
20.8%
Compound Annual Growth
Largest Segment
Prophylactic mRNA Vaccines
Fastest Growing Segment
Mrna Therapies for Protein Replacement
Leading Region
North America
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
42.5% market share
Key Players
BioNTech
Emerging Players
Laronde, ReNAgade Therapeutics
Market Definition & Overview
The mRNA Therapeutics Market involves the development, manufacturing, and commercialization of medicinal products that leverage messenger RNA (mRNA) to instruct the body's cells to produce specific proteins. These proteins can stimulate an immune response against pathogens, replace deficient proteins, or target diseased cells, thereby preventing or treating a wide range of conditions. This market, a key segment of precision therapeutics, focuses on innovative mRNA-based vaccines and therapeutic drugs across various indications, driving significant advancements in personalized medicine and rapid response to global health challenges.
Scope
- Global market analysis across major continents and countries
- Segmentation by application (infectious diseases, oncology, rare diseases)
- Segmentation by product type (prophylactic vaccines, therapeutic drugs)
- Forecast period typically covers 2024 to 2034, with historical data from 2020
Inclusions
- mRNA-based prophylactic vaccines for infectious diseases
- mRNA therapeutic drugs for oncology (e.g., cancer vaccines)
- mRNA therapies for rare genetic disorders and protein replacement
- mRNA vaccines and therapeutics for autoimmune diseases
- Lipid nanoparticle (LNP) and other delivery systems designed for mRNA
- Contract manufacturing and development services for mRNA products
Exclusions
- Traditional protein-based biologics and small molecule drugs
- DNA-based gene therapies and gene editing technologies (e.g., CRISPR)
- Cellular therapies not primarily utilizing mRNA modification
- Research reagents and tools not directly part of a therapeutic product
- Diagnostic products and kits unrelated to mRNA therapeutic development
- Veterinary or animal health applications of mRNA technology
Market Size Forecast
Executive Summary
• The mRNA Therapeutics market is valued at $39.1 Bn in 2025 and is forecast to reach $259.4 Bn by 2035, reflecting a robust CAGR of 20.8% as demand accelerates across every major segment and region over the ten-year outlook.
• Prophylactic mRNA Vaccines leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at 35.5%, while Emerging Areas is expanding the fastest at a 14.0% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 42.5% of global share, anchoring overall demand within its home region throughout the forecast period.
• Therapeutic diversification beyond infectious diseases into oncology and autoimmune conditions, propelled by advanced delivery technologies, will drive the mRNA market's next growth phase, reshaping precision medicine paradigms globally.
• Intensifying competition from Big Pharma’s strategic investments and a surge in biotech innovation are fostering a dynamic, yet consolidating, market landscape, necessitating agile partnership and M&A strategies.
• Evolving regulatory frameworks and breakthroughs in mRNA stability and targeted delivery mechanisms are accelerating clinical pipelines, enabling novel applications across previously intractable conditions and streamlining global approvals.
• Scaling specialized manufacturing capabilities and ensuring resilient global supply chains are critical imperatives, directly influencing market access, cost-effectiveness, and regional therapeutic availability across all key segments.
• Sustained venture capital and strategic partnerships are funneling significant investment into next-generation mRNA platforms, particularly in personalized medicine and emerging therapeutic areas, signaling robust long-term potential.
• While developed markets lead in adoption, targeted investments in emerging economies and expanded indications will drive new growth pockets, demanding localized clinical development and market entry strategies.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Valuation
The mRNA Therapeutics Market was valued at an substantial $39.1 billion in the base year, establishing its significant industry presence.
Future Market Expansion
This market is projected to achieve a valuation of $259.4 billion by the forecast year, underscoring its immense growth potential.
Robust Growth Outlook
The market is set for exceptional expansion, exhibiting a Compound Annual Growth Rate (CAGR) of 20.8% from the base year to the forecast year.
Infectious Disease Leadership
The infectious diseases segment, notably driven by successful vaccine developments, is expected to remain a primary contributor to market revenue.
Pipeline Diversification
A key trend is the increasing diversification of mRNA therapeutic pipelines, expanding beyond vaccines into oncology, rare diseases, and gene editing applications.
Innovation and Investment
Continuous technological innovation and substantial investments from both private and public sectors are accelerating the development and commercialization of new mRNA therapies.
Market Dynamics
Market Trends
- Focus on oncology applications is expanding beyond infectious diseases.
- Increased collaboration between biotech firms and large pharmaceutical companies.
- Automation and AI are streamlining mRNA drug discovery and manufacturing.
- Advancements in lipid nanoparticle (LNP) delivery systems continue to emerge.
Growth Drivers
- High efficacy demonstrated by COVID-19 mRNA vaccines.
- Growing prevalence of chronic and infectious diseases globally.
- Significant R&D investment and government funding for mRNA research.
- Faster development timelines compared to traditional drug platforms.
Restraints
- High manufacturing costs and complex cold chain logistics challenge accessibility.
- mRNA instability and efficient delivery to target cells remain significant hurdles.
- Potential for unwanted immunogenicity raises safety concerns for repeated dosing.
- Navigating complex regulatory pathways can impede rapid market approval and adoption.
Opportunities
- Developing mRNA therapies for rare genetic diseases.
- Expanding applications into autoimmune disorders and cardiovascular diseases.
- Personalized cancer vaccines leveraging advanced mRNA technology.
- Enhanced delivery systems for broader tissue targeting and reduced side effects.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Prophylactic Mrna VaccinesTherapeutic Mrna VaccinesMrna Therapies for Protein ReplacementMrna Therapies for Gene EditingMrna Therapies for Regenerative MedicineMrna Immunomodulators |
| By Technology | Lipid Nanoparticle DeliveryPolymeric Nanoparticle DeliverySelf-Amplifying MrnaNon-Amplifying MrnaCircular MrnaChemically Modified Mrna |
| By Application | Infectious DiseasesOncologyGenetic DisordersAutoimmune DiseasesCardiovascular DiseasesMetabolic DiseasesRare DiseasesOthers |
| By End-User | HospitalsSpecialty ClinicsAcademic & Research InstitutesPharmaceutical & Biotechnology CompaniesContract Research OrganizationsGovernment Agencies |
| By Component | Mrna Active Pharmaceutical IngredientsLipid Nanoparticle ComponentsPlasmid DNAEnzymes & ReagentsBuffers & ExcipientsAnalytical & Purification EquipmentFormulation & Fill-Finish EquipmentOthers |
| By Process | Plasmid DNA ManufacturingIn Vitro TranscriptionMrna PurificationLipid Nanoparticle FormulationAseptic Fill & FinishQuality Control & AssuranceDownstream Processing |
Regional Analysis
- North America leads the mRNA therapeutics market due to substantial R&D investments, a robust ecosystem of pharmaceutical companies, and favorable regulatory support. High healthcare expenditure and significant venture capital funding further solidify its dominance in developing and commercializing innovative treatments.
- The Asia-Pacific region is emerging as the fastest-growing market, driven by increasing government support for biotechnology and expanding research infrastructure. Rising healthcare expenditure and a large, aging population needing advanced therapies are significant growth catalysts.
- Europe is increasingly focusing on building robust domestic mRNA manufacturing capabilities and fostering cross-border research collaborations. This aims to enhance supply chain resilience and accelerate novel therapeutic development, particularly post-pandemic.
Asia Pacific
12.1% CAGR
$8.8 Bn
22.5% share
- The Asia Pacific region is experiencing rapid growth, driven by increasing healthcare expenditure, a large patient pool, and rising investments in biopharmaceutical R&D, particularly in countries like China, Japan, and India.
North America
9.8% CAGR
$13.9 Bn
35.5% share
- North America leads the market due to robust R&D infrastructure, significant investment in biotechnology, and the presence of major pharmaceutical companies driving innovation and product development.
Europe
9.5% CAGR
$10.9 Bn
28% share
- Europe holds a strong market position, supported by advanced healthcare systems, substantial public and private funding for research, and a growing number of clinical trials in mRNA therapeutics.
Latin America
11.2% CAGR
$3.1 Bn
8% share
- Latin America represents a growing market, with increasing awareness and adoption of advanced therapeutics, alongside efforts to improve healthcare infrastructure and access to innovative treatments.
Middle East & Africa
13.5% CAGR
$1.6 Bn
4% share
- The Middle East & Africa region shows significant growth potential from a lower base, fueled by government initiatives to diversify economies and invest in healthcare innovation, coupled with a rising demand for specialized therapies.
Emerging Areas
14.0% CAGR
$782.0 Mn
2% share
- Emerging Areas, encompassing nascent markets, exhibit the highest CAGR due to low market penetration and significant potential for future adoption as healthcare systems develop and access to advanced treatments expands.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $16.6 Bn | 15.8% | The global leader in mRNA therapeutics R&D, manufacturing, and commercialization, driven by substantial public and private investment, a robust biotech ecosystem, and early regulatory approval pathways. |
| 2 | Brazil | $977.5 Mn | 25.0% | The largest market in South America with significant healthcare needs and a vast population, driving demand for innovative vaccines and therapies, alongside growing domestic R&D interest and public health initiatives. |
| 3 | Germany | $3.7 Bn | 16.8% | A pioneer in mRNA technology, boasting leading research institutions and key companies like BioNTech, driving significant R&D, manufacturing, and clinical trials for new mRNA therapeutics. |
| 4 | China | $4.4 Bn | 25.5% | A rapidly growing market with massive investment in biotech, extensive R&D capabilities, and a large population, positioning it as a major force in the development and adoption of mRNA therapeutics through domestic innovation. |
| 5 | Saudi Arabia | $391.0 Mn | 26.0% | A key emerging market in the Middle East, with substantial government investment in healthcare infrastructure and biotech R&D as part of Vision 2030, aiming for self-sufficiency in advanced therapies and regional leadership. |
Countries Covered (22)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Switzerland, Italy, Rest of Europe, China, Japan, South Korea, India, Australia, Taiwan, Rest of Asia Pacific, Saudi Arabia, Israel, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | BioNTech | 5.7% | Leverage deep mRNA expertise and strategic partnerships to develop a broad portfolio of individualized immunotherapies and infectious disease vaccines. | Co-developed the first widely approved mRNA-based COVID-19 vaccine with Pfizer. | Continued expansion of its oncology pipeline through clinical trial advancements for several mRNA-based cancer immunotherapies. | ComirnatyBNT111BNT122+1 |
| 2 | CureVac | 5.4% | Focus on the development of a new generation of mRNA vaccines and therapeutics utilizing its proprietary modified mRNA technology platform. | A pioneer in mRNA technology, known for its extensive research in unmodified and modified mRNA approaches. | Advanced its lead COVID-19 vaccine candidate, CV2705, and influenza vaccine candidates into clinical development. | CV2705CV2502CV0501 |
| 3 | Arcturus Therapeutics | 5.1% | Utilize its self-amplifying mRNA (sa-mRNA) technology and LUNAR lipid nanoparticle delivery platform to develop vaccines and therapies for infectious diseases and rare genetic disorders. | Specializes in self-amplifying mRNA technology, which allows for lower dose requirements and sustained protein expression. | Achieved regulatory approval for its COVID-19 vaccine, ARCT-154, in Japan and advanced trials for its rare disease programs. | ARCT-154ARCT-810ARCT-032 |
| 4 | Gritstone Bio | 4.9% | Develop personalized and off-the-shelf cancer immunotherapies using a unique self-amplifying mRNA approach combined with neoantigen identification. | Focuses on eliciting broad and potent T-cell responses against cancer through neoantigen-specific mRNA vaccines. | Presented positive clinical data for its personalized cancer vaccine GRANITE and initiated a Phase 2b trial for its universal flu vaccine. | GRANITESLATEGRT-R914 |
| 5 | Orna Therapeutics | 4.6% | Pioneer the development of circular RNA (oRNA) therapeutics, which offer potentially enhanced stability and protein production compared to linear mRNA. | Innovating with circular RNA, a novel modality distinct from traditional linear mRNA, for therapeutic applications. | Entered into a significant strategic collaboration with Merck to develop multiple programs across infectious disease and oncology. | oRNA-based cancer therapiesoRNA-based autoimmune therapies |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
BioNTech, CureVac, Arcturus Therapeutics, Gritstone Bio, Orna Therapeutics, Strand Therapeutics, Ethris GmbH, eTheRNA immunotherapies, Nutcracker Therapeutics, ReCode Therapeutics, Ziphius Vaccines, Sana Biotechnology, Beam Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Omega Therapeutics, Entos Pharmaceuticals, Arbutus Biopharma, Acuitas Therapeutics, Evox Therapeutics
The global mRNA Therapeutics market features a competitive landscape led by BioNTech, CureVac, Arcturus Therapeutics, Gritstone Bio, Orna Therapeutics, and Strand Therapeutics, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
BioNTech
CureVac
Arcturus Therapeutics
Gritstone Bio
Orna Therapeutics
Strand Therapeutics
Ethris GmbH
eTheRNA immunotherapies
Nutcracker Therapeutics
ReCode Therapeutics
Ziphius Vaccines
Sana Biotechnology
Beam Therapeutics
CRISPR Therapeutics
Intellia Therapeutics
Omega Therapeutics
Entos Pharmaceuticals
Arbutus Biopharma
Acuitas Therapeutics
Evox Therapeutics
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Moderna's mRNA RSV Vaccine Secures FDA Approval
Moderna's mRNA-1345 vaccine, targeting Respiratory Syncytial Virus (RSV), received FDA approval for older adults. This marks a significant expansion of mRNA technology into established infectious disease markets beyond COVID-19, validating its broad applicability.
BioNTech Reports Positive Early Data for mRNA Cancer Vaccine Candidates
BioNTech announced encouraging initial clinical data for several personalized mRNA cancer vaccine candidates, including in pancreatic cancer. These developments highlight the platform's therapeutic potential for difficult-to-treat cancers, driving mRNA into oncology applications.
Pfizer Commits to Expanding mRNA Technology Beyond COVID-19 with New Pipeline Focus
Pfizer unveiled plans to significantly broaden its mRNA vaccine pipeline, investing in candidates for influenza, shingles, and other infectious diseases. This strategic move reinforces the long-term commitment of a major pharmaceutical player to the versatility and potential of mRNA platforms.
CureVac and GSK Advance Next-Generation mRNA Flu Vaccines to Phase 3 Trials
CureVac and GSK announced the progression of their modified mRNA seasonal influenza vaccine candidates into Phase 3 clinical trials. This milestone showcases the ongoing evolution of mRNA vaccines for established infectious diseases, aiming for improved efficacy and broader protection.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $39.1 Bn |
| Market Size (Forecast) | $259.4 Bn |
| CAGR | 20.8% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 22 Countries |
| Segments Covered | 6 Segments, 41 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included